Opportunities to bridge the technology gap between academia and industry.

1. Opportunities to bridge the technology gap between academia and industry. The view from one pharma

2. AstraZeneca • Major world wide Pharma • Active in more than 100 countries world wide • 2008 sales of $31.6 billion • >3% increase on 2007 • 65,000 employees world wide • 12,000 staff in R&D • >$5 billion invested in R&D • 17 principle R&D centers across 8 countries • Focus on 6 therapy areas • Oncology • Cardio Vascular • Respiratory and Inflamation • Infection • Neuroscience • Gastrointestinal

3. Pipeline of NCEs as of Jan 2009 • Phase 1 trial • 23 small molecules • 10 biologicals • Phase 2 trials • 26 small molecules • 5 biologicals • Phase 3/ registrations • 9 small molecules • 1 biological • Data from 2008 annual report

4. Acquisitions and Licensing • 35-40 major business development transactions (2008 annual report) • Some examples of recent acquisitions • Biologicals • Cambridge Antibody Technologies • MedImmune • Infection • Arrow Therapeutics • Oncology • KuDos Pharmaceuticals • Licensing • 11 of the NCEs currently in clinical trials are partnered products

5. Links with Academic Institutions • Within the UK • 2008 started collaboration with Cancer Research UK – Linking an AstraZeneca development compound with the charities Clinical Development Partnership program • Royal Marsden NHS foundation trust – accessing imaging technology to study the impact of Recentin on solid tumours • Manchester University – strategic alliance to look at imaging biomarkers. In addition there are links through Manchester University to the National Cancer Centre Singapore • Newcastle University – linked with Astrazeneca via Cancer Research Technology Ltd and KuDOS to study DNA-PK inhibitors • MRC – 4 PhDs • BBSRC – AstraZeneca linked with the Babraham Institute • Division of Signal Transduction Therapy – University of Dundee

6. Links with Overseas Academics • ICC – Innovation Centre China ($100M investment) • University of Washington St Louis – Investigation in to Alzheimer’s Disease to find better ways of diagnosis and treatment • Columbia University Medical Center – Identification of new targets and novel therapies for type 2 diabetes and obesity • Virginia Tech and Mayo Clinic – licensing agreement for the triple reuptake inhibitor for treatment of depression • University of Texas MD Anderson Cancer Center – Studying cancer related pain • Clinical studies and alliances with several US cancer institutes including Mass General Hospital, Vanderbilt-Ingram Cancer Center, University of Colorado and National Cancer Institue

7. Technology Collaborations • Silence Therapeutics – novel system for using siRNA molecules to target respiratory disease • Cell Signaling Technology – PhosphoScan R – CST generated antibodies to phosphorylated peptides used to IP proteins from cell lysates. These are analysed by LC-MS to monitor changes in the levels of phosphorlyation within the cell during treatment with potential kinase inhibitors • Astex Therapeutics – fragment based drug discovery – expertise in NMR screening, crystalography and Isothermal calorimetry

8. Building a partnership with AstraZeneca • Strategic Planning and Business Development (SPBD) Group • Main role is to manage in-licensing activities • Aligned with therapy areas • Also involved with out licensing, spin offs, risk sharing deals • Established a Master agreement system for main collaborators • Manchester Cancer Research Centre • Royal Marsden Hospital • NKI-AVL – Netherlands Cancer Institute • Strategic Alliances Group • Science and Technology Alliances Group • Collaborations relating to technology which is applicable across therapy areas • Advanced Science and Technology Lab – ASTL

9. Areas of interest • Chemistry • New synthetic methodologies • Novel lead generation technologies • Predictive QSAR methodologies • Predictive Biology • High Content Screening technologies • Novel physiological cell based efficacy screening technologies • Target validation methodologies • Improved methodologies to predict safety/toxicity • In silico simulation • In vivo predictive models • In vivo imaging • Predictive medicine • Rapid biomarker analysis techniques • Imaging to provide functional measurements of disease activity • Knowledge management/informatics • Structured searching and text mining • Patent informatics

10. Funding • Internal Innovation funding • <$1M • Should not include capital purchases • Aim to identify new and novel technologies to improve our lead generation screening capability • Partnerships with charitable organisations and governments • BBSRG, MRC etc • Corporate funding • Direct from research areas – very limited • Risk sharing deals • AZ contribute with resources and knowledge • FTE • Lab space • Compound libraries • Chemistry • In vitro/ In vivo testing • Share rewards between AZ and academic/biotech

11. What can AZ offer • Large and ever expanding compound collection • 4 HTS centres across the globe supporting 6 therapy areas • 2 in UK • 1 in Sweden • 1 in USA • Highly automated screening platforms for both primary and secondary screening • Systems from many suppliers • Beckman – motorman core systems • Agilent (V11) - Biocells • The Automation Partnership - Asset • RTS • HighRes Biosolutions – Microstar systems • ThermoFisher – CRS F3 automation systems • PAA – Elisa workstations and integrated acoustic dispensing systems • Extensive experience and proven track record in drug discovery • Technology teams (ASTL, CTT) – role is to evaluate new technologies

12. Contact information • Chris Yochim – SPBD External Relations chris.yochim@astrazeneca.com • Iain Comley – Science and Technology Alliances iain.comley@astrazeneca.com • Kay Tait – Oncology and Infection SPBD kay.tait@astrazeneca.com • Jonathan Wingfield – Cancer Technology Team jonathan.wingfield@astrazeneca.com